Sungphil Kim, General Manager of Cytiva Korea, discusses his vision for strengthening Korea’s biopharma ecosystem through customer-centricity, talent development and innovation. He highlights Cytiva’s Songdo hub, support for advanced therapies, AI and automation, and practical training through Fast Trak™. Kim believes that Korea has the manufacturing expertise, ambition and ecosystem potential to become a global biopharma leader, while emphasising imagination as the foundation of his leadership philosophy.
You are six months into your role as General Manager of Cytiva Korea. What have been your key priorities since joining?
It may sound simple, but the answer is our customers. One of Cytiva’s core values is to listen to customers and act on what we hear, and that is the orientation I have been working to build across the organisation from day one. The starting point is understanding what our customers in Korea are actually facing right now: escalating competition, significant uncertainty from geopolitical risk and supply chain disruption, regulatory change – and at the same time, genuine opportunity. A wave of blockbuster biologics will go off patent in the next four to five years, and the Korean government is investing heavily in building a biopharma ecosystem. There is real momentum here.
When I look at what our customers need most, it comes down to four things: efficiency, flexibility, sustainability, and the transition to new modalities and advanced therapies. I believe Cytiva is well positioned to support on all four, with an end-to-end platform that spans monoclonal antibodies, mRNA, and cell and gene therapy – both upstream and downstream, and from research through to manufacturing.
The second priority has been strengthening and transforming the organisation itself, building a genuinely customer-centric mind-set across every function. And the third, which is close to my heart, is talent development – not just within Cytiva, but contributing to the broader ecosystem. There is a recognised talent shortage in bioprocessing, and we have a role to play in addressing that, including through our Fast Trak™ centre here in Korea.
How significant is Korea to Cytiva and Danaher globally, and what drew you personally to this industry?
Within the global pharmaceutical industry, Korea generally ranks between the 10th and 15th largest markets. Yet for Cytiva, Korea consistently ranks among our top markets worldwide. That is quite remarkable for a country of this size and underscores both the rapid growth of Korea’s biopharmaceutical sector and the strong, long-standing partnerships we have built with our customers. The market’s innovation, ambition, and global influence make Korea a strategically important part of Cytiva’s and Danaher’s long-term growth story.
On a personal level, the reason I moved into this industry is that I wanted to contribute to the growth of Korean pharma. When I was completing my MBA about fifteen years ago, I thought carefully about which industry to dedicate my career to. I looked at banking, consulting, defence, and pharma. I chose biopharma because I believed it had a significant future, and it has grown even faster than I anticipated. Being in a position now where I can contribute directly to that growth, and to the broader ecosystem, is something I feel genuine conviction about.
Cytiva recently made a significant investment in an Innovation Hub in Songdo. What was the strategic rationale, and what does it offer?
This is a strategic investment that reflects our belief in the future of Korean biopharma. The latest Cytiva Global Biopharma Index ranks Korea third globally, up from around twelfth place in 2023, underscoring the industry’s rapid advancement in innovation, digital capabilities, and overall competitiveness. We want to be better positioned to support our customers as that trajectory continues.
The Songdo site is not simply a manufacturing facility. It is an integrated platform. At its core is the manufacturing capability, which enables us to provide more flexible lead times and ensure the quality standards our customers require. Alongside that, we offer Fast Trak™ consulting and process development support, advanced technology demonstrations, and training programmes for both industry and academia. The vision is for it to function as an innovation hub that contributes to the broader Korean biopharma ecosystem – serving CDMOs, emerging biotechs, and academic institutions, in addition to our existing commercial partners.
Who are your primary clients in Korea today, and how do you see that evolving?
CDMOs currently represent the largest share of our business and play a critical role in the growth of Korea’s biopharmaceutical ecosystem. In addition, a new generation of Korean biopharma companies is emerging with strong innovation capabilities and global ambitions.
I believe that within the next five to ten years, we will see more Korean companies showcasing groundbreaking clinical data at leading international conferences such as ASCO, ESMO, and ADA. As the industry evolves from scale-driven growth to innovation-led growth, I am confident that Cytiva will play a pivotal role in enabling that transition.
How are you making the case for Korea within Danaher’s global leadership?
Danaher and Cytiva’s global leadership already understand that Korea is an important and growing market. What I need to demonstrate is the specific value of our Innovation Hub model – that Korea can be a centre of manufacturing excellence, demonstration, collaboration, and ecosystem contribution. Execution is everything in that argument. If we perform at the highest level here, the confidence from our parent company will follow.
I am genuinely optimistic about Korea’s trajectory, and I have been for a long time. One reason Korea was slower to develop in biopharma historically was that domestic demand was insufficient. That is changing. Korea’s ageing population is now crossing a genuine inflection point in local healthcare demand. And there is a second factor that I think is underappreciated: biopharmaceutical manufacturing at its core is about precision control of complex biological production processes. Korea has deep capability in exactly that kind of disciplined, high-precision manufacturing through its semiconductor and electronics industries. I believe that foundation transfers directly to biopharma, and it is part of why I am confident Korea will become one of the major biopharma countries in the world within the next decade.
What is in highest demand from your customers today, and where do you see growth going forward?
Monoclonal antibody bioprocessing – upstream and downstream – remains our primary revenue driver, and that is not changing in the near term. But when I look forward, cell and gene therapy is the area that demands the most attention. We do not know exactly when cell and gene therapy will cross the innovation chasm, but we know it will. For cell therapy, the critical transition to watch is from autologous approaches in blood cancers toward allogeneic treatments targeting solid tumours. In gene therapy, the progression is from rare diseases toward more chronic conditions. I am watching the clinical trial landscape closely and seeing genuine progress. Cytiva has the technology and products to support that transition, which positions us well as these modalities mature.
How do you support major CDMOs as they respond to global demand and regulatory standards?
Efficiency and flexibility are the two things CDMOs need most from us, alongside absolute reliability on quality and delivery. Our success should be measured by our customers’ success, and that means starting with the fundamentals: on-time delivery, consistent quality, and responsive local service. One of the key reasons for the Songdo investment was to give us more manufacturing flexibility for local delivery. We also have a strong local service team that can respond quickly should customers have issues. And where problems require specialist expertise, we can draw on Cytiva’s extensive global network of technical experts. That combination – local responsiveness and global depth – is how we support customers operating at the scale of Korea’s major CDMOs.
How does your team development agenda connect to the AI and automation questions your customers are raising?
The mind-set shift is more important than the skills alone, though both matter. Because Cytiva offers such a broad portfolio, my team needs to be capable of advising on the full picture and providing holistic solutions, not just recommending products they know best. I am building that capability systematically across all functions.
On automation and AI, Korean customers are genuinely forward-looking and actively requesting our expertise. The biopharma industry still relies heavily on manual steps and digital maturity is relatively limited, but the direction is clear. What customers need is real data utilisation, connectivity across platforms, and prediction-based decision-making. Our approach is to tailor our support to where each customer actually is in their digital journey, using Cytiva’s portfolio and global network to meet them there.
Can you explain how the Fast Trak™ model works in practice?
It operates in two distinct ways. The first is process development and optimisation consulting, where customers come to us with specific development challenges and we work through them together. There is a level of cost recovery, but our primary motivation is contribution to the ecosystem. The second is training and education, through partnerships with universities including Seoul National University, Yonsei University, Inha University, and SoonchunhyangUniversity. Students come to our Fast Trak™ facility and work on our actual equipment. That practical, hands-on exposure is the kind of training the industry genuinely needs and is difficult to replicate in a classroom. It is one of the most direct ways we contribute to building the talent pipeline Korean biopharma will need as it grows.
Where do you see the opportunities and challenges as Korea pursues its ambition to become a global biopharma hub?
I see more opportunity than challenge. But the honest assessment is that Korea is still behind China, Europe, and the United States in ecosystem maturity, and closing that gap requires more systematic and aggressive government investment – particularly focused on building a genuine biotech ecosystem. The model of one large pharma company doing everything end to end is no longer viable for advanced therapies. The cost and complexity require a functioning ecosystem of specialised companies working together: biotechs, CDMOs, technology providers, academic institutions. Korea is making real progress, but there is significant work still to be done, and investment needs to be directed there with genuine commitment.
Sustainability is a major commitment for Danaher and Cytiva globally. How does that translate locally?
Within five days of joining Cytiva, I went through mandatory sustainability training. That told me something important about the company’s priorities. Danaher’s commitment is to achieve net zero by 2050, built around three pillars: decarbonising our products, validating our manufacturing sites against clear sustainability standards, and demonstrating leadership in the space. What gives me confidence is that these are not simply aspirations. We have clearly defined short-, medium- and long-term milestones, measurable KPIs, and transparent reporting. That includes reducing carbon emissions, improving packaging and plastics, and embedding sustainability into product design and sourcing. We measure our progress carefully and hold ourselves accountable against those targets. I believe that positions Cytiva to become one of the industry’s sustainability leaders.
What I find meaningful is that sustainability is not just an internal objective. Our major customers ask us how we are performing and request our data. That makes it part of how we serve customers, which is the right framing for embedding it in day-to-day culture rather than treating it as a compliance exercise.
Where do you want to take Cytiva Korea in the next five years?
In a recent leadership workshop, I opened the discussion with a simple yet thought-provoking question: “What do you imagine in seven years?” That question matters to me. What I imagine is Cytiva being recognised as a company that genuinely contributed to the development of the Korean biopharma industry. I want to see the biosimilar business grow, the CDMO relationships deepen, and our Innovation Hub become a proof point that validates to our global headquarters that Korea is the right place to invest. But beyond the business metrics, what I most want is for people in Korea to think of Cytiva as a company that helped build something that matters here. That is the reputation I am working toward.
How has your leadership philosophy evolved over your career?
My definition of leadership has changed several times. For a long time, I defined it as helping my team achieve aspirational goals by making them more effective and removing obstacles in their way. That is still important. But more recently I have come to believe that leadership is fundamentally about imagination. My role is to share what I imagine, to understand what my team imagines, to synchronise those visions, and then to motivate the organisation to pursue them together. The first step is always conversation, not instruction. You cannot push imagination from the top down. It has to emerge through genuine exchange.
I find imagination becoming more and more important to me – both personally and as a leader, as I progress in my career. I want my team to dream about what is possible, and I want to create the conditions for that.
Finally, is there a message you would like to leave our readers?
My final message is one of optimism. I have great confidence in the future of Korea’s biopharma industry. While some people question where the next phase of growth will come from, I believe the opportunities remain significant.
Having recently stepped into this role, I find myself becoming even more optimistic with every conversation I have. There is a real sense of energy and ambition across the industry. I am looking forward to learning from our customers, building new relationships, and being part of the next chapter of growth for Korean biopharma. The next chapter of Korea’s biopharma story is still being written, and I believe it will be a remarkable one.
